Efficacy DataEfficacy data on tumor types with larger commercial opportunities, such as ovarian, endometrial, and lung cancers, remain limited.
Financial PerformanceIMTX shares dropped 16%, suspected to be related to the surprising decision to announce an equity financing.
Safety ConcernsOne possible Grade 5 treatment-related adverse event of fatal sepsis was disclosed, highlighting a severe safety concern.